Dec 06, 2020 8:15am EST Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting
Dec 03, 2020 7:10am EST IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer
Nov 13, 2020 7:05am EST IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy
Nov 12, 2020 7:05am EST IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update
Nov 10, 2020 7:05am EST IMV Strengthens Leadership Team with Appointment of Andrew Hall as Chief Business Officer
Nov 09, 2020 8:00am EST IMV’s T Cell Therapy Demonstrates 86% Objective Response Rate in Combination with Merck’s Keytruda® in PD-L1 Positive Patients with r/r DLBCL
Nov 04, 2020 5:05pm EST Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV’s T Cell Therapy in Combination With Merck’s Keytruda® in Patients With r/r DLBCL to Be Presented at The American Society of Hematology Annual Meeting
Oct 29, 2020 7:05am EDT IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers Associated With Clinical Response in Patients With r/r DLBCL treated with DPX-Survivac Combination Therapy
